Heart failure (HF) remains one of the world’s most urgent cardiovascular challenges—common, costly, and clinically complex. Despite major advances in medications, devices, and care pathways, HF continues to drive high rates of hospitalization and long-term disability, especially among older adults and patients living with multiple comorbidities. A central problem is heterogeneity: people with HF can look similar at the bedside yet have very different underlying biology, trajectories, and responses to therapy.
A recent review in Current Cardiology Reviews synthesizes recent evidence and outlines how the field is moving from broad categories—largely organized around left ventricular ejection fraction (LVEF)—towards a precise, mechanism-based approach that aims to match the right intervention to the right patient at the right time.
A changed therapeutic foundation: benefits across the EF spectrum
One of the most consequential shifts in contemporary HF care is the expansion of therapies beyond traditional EF “silos.” Sodium–glucose cotransporter-2 inhibitors (SGLT2i), originally developed for diabetes, have demonstrated consistent reductions in HF hospitalization and cardiovascular events across LVEF categories, supporting their role as a cornerstone therapy even in many patients without diabetes. This broad efficacy reinforces a growing emphasis on disease mechanisms—metabolic, renal, hemodynamic—rather than relying solely on phenotype labels.
At the same time, angiotensin receptor–neprilysin inhibitors (ARNIs), particularly sacubitril/valsartan, have further advanced outcomes in HF with reduced EF and may offer benefits in selected subgroups of HF with preserved EF. Together with beta-blockers and mineralocorticoid receptor antagonists, these agents help form a contemporary “multi-target” base that is increasingly initiated earlier and more efficiently in clinical practice.
Treating the “right disease”: comorbidities and specific etiologies
Beyond mainstream HF pharmacotherapy, the review underscores progress in diagnosing and treating previously under-recognized HF drivers—especially in older adults. Transthyretin cardiac amyloidosis (ATTR) is highlighted as a now-treatable cause of HF, where timely recognition through non-invasive imaging and biomarker strategies can open the door to disease-specific therapies such as transthyretin stabilizers.
The article also emphasizes iron biology as a modifiable contributor: iron deficiency is common, measurable, and treatable in HF, with intravenous iron formulations improving symptoms and functional capacity in appropriate patients. Conversely, iron overload syndromes can cause restrictive cardiomyopathy and arrhythmias, where advanced imaging (notably cardiac MRI T2*) can quantify myocardial iron and guide chelation therapy decisions.
Devices, monitoring, and the rise of proactive care
Innovation is not limited to medications. Evolving device strategies—cardiac resynchronization therapy (CRT) in selected patients, durable LVAD technologies, and implantable hemodynamic monitors—support a shift from reactive decompensation management to proactive risk detection and personalized fluid optimization. By detecting early physiologic changes, these tools can enable earlier interventions that may prevent hospital admissions and preserve quality of life.
Precision medicine: biomarker panels, multi-omics, and AI
A core theme of the review is the growing feasibility of precision medicine in HF. Traditional biomarkers such as BNP/NT-proBNP remain essential for diagnosis and monitoring, but emerging markers—reflecting fibrosis, inflammation, myocardial injury, and cardiorenal stress—can provide a more multidimensional profile of a patient’s disease. The review describes how combining markers (for example, natriuretic peptides with soluble ST2 and galectin-3) may improve risk stratification and better inform treatment intensity and follow-up planning.
Genetic testing and transcriptomic profiling are also beginning to reveal HF “endotypes,” particularly within the diverse HFpEF population, where conventional approaches have historically underperformed. Artificial intelligence and machine learning add another layer: models trained on large datasets can support early detection of deterioration, improve interpretation of echocardiography and ECGs, and generate dynamic risk scores that respond to real-time clinical changes.
The unfinished work: equity, representation, and implementation
While progress is real, the review emphasizes persistent barriers that may limit impact unless addressed head-on. Key patient groups remain underrepresented in clinical trials—especially women, older adults, multimorbid patients, and populations from low- and middle-income settings—reducing confidence that “average trial results” translate fairly to real-world patients. In addition, uptake of guideline-directed medical therapy can be inconsistent due to cost, therapeutic inertia, fragmented care systems, and unequal access to specialty services and digital tools.
A call to action: precision that is practical, interpretable, and equitable
The review concludes that the next era of HF care must move beyond LVEF alone and adopt multidimensional phenotyping (biomarkers, imaging, genomics, comorbidities, and social determinants) alongside multidisciplinary care models. To make precision medicine real—not just aspirational—health systems will need inclusive pragmatic trials, scalable digital infrastructures, value-aligned reimbursement, and a focus on patient-centered outcomes such as function and quality of life.
Article Title: Heart Failure in the Era of Precision Medicine: Advances, Challenges, and Future Directions
Read the published article here: https://bit.ly/4d5BLuN
JOURNAL
Current Cardiology Reviews
DOI: 10.2174/011573403X433317251107113544
If you want to publish your article please visit : https://bit.ly/4de0DRi
Journal
Current Cardiology Reviews